Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Beigene Ltd ADR (NQ: BGNE )

236.90 +9.17 (+4.03%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Beigene Ltd ADR

< Previous 1 2 3 4 5 6 7 Next >
Mirati's Sitravatinib Flunks Phase 3 Combo Therapy Study In Type Of Lung Cancer Setting
 
Via Benzinga
Immix Biopharma's Subsidiary Says Investigational CAR T Therapy Shows 100% Response Rate In Amyloidosis
Immix Biopharma Inc's (NASDAQ: IMMX) subsidiary Nexcella Inc announced updated AL Amyloidosis clinical data from its ongoing Phase 1b/2a NEXICART-1 study of its BCMA-targeted chimeric antigen receptor... 
Via Benzinga
Recap: BeiGene Q1 Earnings
 
Via Benzinga
What's Going On With Immix Biopharma Stock Today
Immix Biopharma Inc (NASDAQ: IMMX) announced early interim data from IMMINENT-01 Phase 1b/2a trial combining tissue-specific therapeutic IMX-110 with BeiGene Ltd (NYSE: BGNE) / Novartis AG' 
Via Benzinga
3 Top Biotech Stocks Defying the Bear Market
All three companies have therapies with strong sales potential. 
Via The Motley Fool
BeiGene's Tislelizumab/Chemo Combo Hits Primary Goal In Gastric Cancer Study
 
Via Benzinga
Why BeiGene Stock Jumped Thursday
A collaboration deal helped send the Chinese biotech stock higher. 
Via The Motley Fool
BeiGene Earnings Perspective: Return On Capital Employed
 
Via Benzinga
4 Analysts Have This to Say About BeiGene
 
Via Benzinga
FDA Approves BeiGene's Brukinsa For Chronic Lymphocytic Leukemia
 
Via Benzinga
7 Biotech Stocks That Could Cure Your Portfolio Woes
If you want to revitalize your portfolio with some exciting opportunities, these biotech stocks to buy might fit the bill. 
Via InvestorPlace
Analysts At H.C. Wainwright & Co. Set 12-Month Target Of $15 Per Share For ENLV Thanks To High Profile Collaboration Agreement, Multiple Ongoing Clinical Trials
This month, H.C. Wainwright & Co. 
Via Benzinga
Hillstream BioPharma's Drug Candidate HSB-1216 Could Be One To Watch As Global Oncology Market Continues To Grow
A surge in oncology drug development, coupled with increased patient access and early diagnosis, has resulted in a massive increase in global spending on cancer treatments. Due to this, the global... 
Via Benzinga
Enlivex, Beigene Collaborate To Test A New Combination Treatment To Fight Advanced-Stage Solid Tumors
This month, Enlivex Therapeutics Ltd. 
Via Benzinga
Zymeworks Cancer Candidate Shows Objective Response Of 41% In Bile Duct Cancer
 
Via Benzinga
BeiGene Earnings Perspective: Return On Capital Employed
 
Via Benzinga
What 5 Analyst Ratings Have To Say About BeiGene
 
Via Benzinga
Will Investors Notice Exciting Sign On BeiGene's Chart?
 
Via Benzinga
Silicon Valley Bank Collapse Might Have Limited Impact On Asia, But Confidence Seems Shaken
Some Asian firms have disclosed cash deposits at troubled U.S. lender Silicon Valley Bank (NASDAQ: SIVB), known for its deep ties with the healthcare and tech sector. Most emphasized that the amounts... 
Via Benzinga
Nasdaq, S&P 500 Futures Rebound In New Trading Week But Rising Bond Yields Remain A Risk
US stocks are coming off a lackluster week and early indications suggest a reversal in sentiment in the new trading week. While rising bond yields could be a cause of concern, the recent weakness could... 
Via Benzinga
Week In Review: Keymed/Lepu Sign $1.2 Billion Deal Out-Licensing Claudin 18.2 ADC To AstraZeneca
Keymed Bio and Lepu Biopharma out-licensed global rights for their antibody drug conjugate to AstraZeneca in a deal that includes $63 million upfront. Meanwhile, the $937 million agreement between... 
Via Talk Markets
Five Best And Worst Performing Healthcare Stocks In January 2023
After a sub-par performance in 2021, healthcare stocks outperformed the S&P 500 in 2022. As well, 2023 is expected to be another promising year for the sector. Let’s take a look at the five best and... 
Via Talk Markets
Is Johnson & Johnson Still a Good Dividend Stock to Buy?
A disappointing fourth-quarter performance has some investors worried about the giant healthcare conglomerate's outlook. 
Via The Motley Fool
Five Best And Worst Performing Healthcare Stocks In December 2022
Multiple factors are expected to help the healthcare industry overcome inflationary pressures. If you are looking to invest in this sector, then to help you select, here are the five best and worst... 
Via Talk Markets
Draganfly To Rally Around 87%? Here Are 10 Other Analyst Forecasts For Friday
SVB Leerink raised the price target for BeiGene, Ltd. (NASDAQ: BGNE) from $236 to $300. SVB Leerink analyst Andrew Berens maintained an Outperform rating. BeiGene shares rose 2% to $279.90 in... 
Via Benzinga
These Were The Five Best And Worst Performing Large-Cap Stocks In Q4 2022
The year 2022 proved to be the worst calendar year for the S&P 500 since 2008. The benchmark index dropped more than 5% in December and almost 20% for the full year. Let’s take a look at the five best... 
Via Talk Markets
Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors
Biopharma stocks were not immune to the broader market downturn seen for much of 2022. 
Via Benzinga
Week In Review: Boston Scientific Pays $523 Million For Majority Stake In Beijing Acotec Scientific
Boston Scientific will pay $523 million for a 65% stake in Acotec Scientific, a Beijing medical device company. Boston Scientific said the acquisition will build up its presence in China, and it will... 
Via Talk Markets
PayPal To Rally Around 47%? Here Are 10 Other Price Target Changes For Monday
 
Via Benzinga
BeiGene Stock Shows Market Leadership With Jump To 82 RS Rating
On Thursday, China-based BeiGene stock cleared that desired 80-plus benchmark, with a jump to 82 from 77 a day earlier. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.